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ABSTRACT
One of the most severe pathologic responses of RSV
infection is associated with overproduction of cytokines
and inflammation, leading to mucus hypersecretion.
This study investigated the role of IL-25 in the develop-
ment of RSV-associated immunopathology. IL-25 and
its receptor IL-17RB were increased following RSV in-
fection, and IL-25 blockade using neutralizing antibod-
ies reduced RSV-associated pathology, AHR, and type
2 cytokine production. Likewise, IL-17RB/ mice dem-
onstrated a modified inflammatory response during
RSV infection characterized by decreased Th2 and in-
creased Th17 cytokine production. Additionally, the IL-
17RB/ mice demonstrated significantly reduced in-
flammation and cytokine production in a model of RSV-
driven asthma exacerbation. These results indicate that
IL-25 regulates the inflammatory response to RSV in-
fection and that its inhibition may enable a reduction in
the severity of RSV-associated pulmonary inflamma-
tion, including during viral-induced asthma exacerba-
tion. J. Leukoc. Biol. 95: 809–815; 2014.
Introduction
RSV is a ubiquitous pathogen and the most common cause of
hospitalization in the first year of life [1–3]. Upwards of 95%
of children have been exposed to the virus by age 2, and al-
though subsequent infections are generally less severe, RSV
represents a difficult target for the adaptive immune system in
that T and B cell memory is not fully protective and does not
prevent reinfection from occurring throughout life [4]. Op-
portunistic infections with RSV can have significant impacts on
elderly and immunocompromised populations and present
with variable symptoms ranging from asymptomatic illness to
bronchiolitis, requiring hospitalization, and in the most severe
cases, death, as a result of respiratory failure [5–7]. Initial at-
tempts to generate a vaccine against RSV ended in failure
when individuals inoculated with an inactivated virus became
hyper-responsive to subsequent RSV infection, causing pro-
found type 2 inflammation, mucus hypersecretion, and pulmo-
nary eosinophilia [8]. The clinical importance of RSV and the
absence of an effective vaccine make understanding immune
regulation of RSV infection an important area of research.
IL-25 (IL-17E) is an IL-17 family member that regulates mul-
tiple aspects of mucosal immunity by promoting type 2 inflam-
mation and production of IL-4, IL-5, and IL-13 [9]. Previous
studies have suggested that IL-25 can have a significant role in
RSV-induced immune responses [10]. We investigated the role
of IL-25 in the pathogenesis of RSV, specifically, how inhibi-
tion of IL-25-mediated signals may alter the development of
RSV-associated immunopathology. Here, we report that IL-25
is up-regulated following primary RSV infection and that peak
cytokine expression corresponds with the intensity of inflam-
mation. Our findings indicate that IL-25 and its receptor, IL-
17RB, play an important role in the establishment of type 2
immunopathology in RSV infection. Furthermore, using a
model of RSV-associated exacerbation of allergic airways dis-
ease in the absence of IL-17RB, a reduction in type 2 cytokine
production and pathology was observed. Thus, IL-25 (IL-17E)
and its receptor may be relevant targets for RSV-induced dis-
ease and provide a therapeutic and diagnostic cytokine to fol-
low during disease for a predictive measurement of severity.
MATERIALS AND METHODS
Animals
Female mice were purchased from The Jackson Laboratory (Bar Harbor,
ME, USA). IL-17RB/ mice were from Amgen (Thousand Oaks, CA,
USA) and bred at the University of Michigan. Animal experiments were
approved by the University of Michigan University Committee on Care.
RSV
Our laboratory used two clinical isolates of the antigenic subgroup A strain
of RSV, Lines 19 [11] and A2-20 [12]. Both have been demonstrated in
animal models to mimic human infection by stimulating mucus produc-
tion, promoting AHR, and increasing IL-13 [12, 13]. Line 19 virus was used
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for BALBc mice, whereas the A2-20 strain was used for C57BL/6J mice,
including IL-17RB/ animals.
Viral exacerbation model
To simulate RSV exacerbation of allergic airway disease, C57BL/6J and IL-
17RB/ mice were sensitized to allergen on Days 0 and 14 and then inoc-
ulated with RSV on Day 17 of allergen sensitization. Mice then received
additional allergen challenges on Days 21 and 23, with harvest on Day 24,
as described [14].
Measurement of AHR
AHR was measured using mouse plethysmography, which is designed spe-
cifically for the low tidal volumes as a direct measure of pulmonary func-
tion, as described [13]. Airway resistance was measured in a closed plethys-
mograph by directly assessing tracheal pressure and comparing the level
with box pressure changes using direct ventilation methodology. Once
baseline levels had stabilized, a methacholine challenge was given via tail
vein. The response was monitored, and the peak airway resistance was re-
corded as a measure of AHR.
Lung histology
Mouse lungs were perfused with 10% formalin (Sigma-Aldrich, St. Louis,
MO, USA), instilled directly into the trachea, then immersed in 10% for-
malin solution overnight at room temperature, and stained with H&E or
PAS.
LN restimulation
Draining mediastinal LNs from mice were isolated, and single-cell suspen-
sions were obtained, as described above for in vitro experiments. LN cells
(4105/well in triplicate) were restimulated with 10 l mL1 allergen, 10
ng mL1 IL-25, or both. RNA was isolated after 2 h in culture; supernatants
were analyzed after 48 h in culture.
Flow cytometry
Analyses of pulmonary cell populations were assessed using standard tech-
niques. Data were collected on a LSR II flow cytometer (BD Biosciences,
San Jose, CA, USA) and on a FACSAria (BD Biosciences) and analyzed us-
ing FlowJo software (Tree Star, Ashland, OR, USA). The following mAb
were obtained from BD Biosciences: CD8a-PE, CD11c-PE, CD125-PE, CD80-
PE, CD86-PE, Nk1.1-PE, CD11b-PerCP-Cy5.5, MHC II(I-Ad)-APC, and Ly-
6G-PeCy7; from BioLegend (San Diego, CA, USA): CD4-FITC, CD8a-FITC,
B220-FITC, CD8a-PE, Ly-6C-PE, CD3-PeCy7, ScaI-Pe-Cy7, CCR3-AF647, Gr-1-
AF700, IL-7R- APC-Cy7, and streptavidin-APC-Cy7; from eBioscience (San
Diego, CA, USA): CD4-PeCy7, CD11c-APC-Cy7, Gr-1-PB, CD49b-PE, F4/80-
PE, and FcR1a-AF647. Mouse anti-mouse IL-17RB was provided by A. L.
Budelsky (Amgen, Seattle, WA, USA) and biotinylated for use in flow cy-
tometry. The cell-surface markers of spleen cell controls were not altered
by the collagenase treatment compared with untreated cells.
Quantitative PCR
Studies to quantitate mRNA were assessed using Real-Time PCR and re-
agents (Life Technologies, Grand Island, NY, USA), as described previ-
ously, with quantitation of fold increase with the 2 comparative thresh-
old method [15].
Statistical analysis
Data were evaluated by one-way ANOVA and where appropriate, evaluated
further with the parametric Student-Newman-Keuls test for multiple com-
parisons or the nonparametric Mann-Whitney rank-sum test.
RESULTS AND DISCUSSION
IL-25 and its receptor IL-17RB are expressed and
participate in RSV-induced airway disease
Previous studies have identified that IL-25 participates in Th2-
associated responses linked to changes in pathophysiology in
Figure 1. Expression of IL-25 and its receptor IL-17RB in lungs of
RSV-infected Balb/c mice is associated with cytokine responses and
T cell cytokine expression. (A) IL-25 and (B) IL-17RB mRNA expres-
sion are both up-regulated during RSV infection in the lungs and (C)
correlates to increased expression of RSV-induced cytokines, IFN-,
and IL-13. (D) Quantitative PCR analysis of RSV-restimulated LN
cells from 8-day-infected animals, with or without IL-25. *P0.05. (E)
Flow cytometry of reactivated T cells from RSV-infected mice demon-
strates that CD4 IL-17RB cells (blue line) preferentially express
increased transcription factors, GATA3 and T-bet, whereas CD8 T
cells did not. Data represents mean  se from five mice.
810 Journal of Leukocyte Biology Volume 95, May 2014 www.jleukbio.org
the lung [15–17]. The results of the present study indicate
that IL-25 represents a target associated with pathogenesis of
severe lower respiratory tract infections. Type 2 cytokines—IL-
13, in particular—act as primary mediators of mucus hyperse-
cretion, and the ability of IL-25 to promote Th2 cytokine pro-
duction may therefore contribute to airway obstruction associ-
ated with poor clinical outcomes. In our initial experiments,
we sought to characterize whether IL-25 was expressed during
the inflammatory response to RSV infection temporal expres-
sion of Il-25 (Fig. 1A) and IL-17RB (Fig. 1B) lung transcripts
(Fig. 1). Transcripts of both genes increased following infec-
tion, peaking between Days 4 and 8 and returning to baseline
levels by Day 12. These responses correlated well with other
potentially pathogenic cytokines produced within the lungs of
RSV-infected mice, including IL-13 and IFN- (Fig. 1C). To
understand further the relationship of IL-25 and T cell activa-
tion, lung draining LNs from infected mice were stimulated
with IL-25, RSV, or the combination. The data in Fig. 1D illus-
trate that IL-25 enhanced not only Th2 cytokines IL-5 and
IL-13 but also Th1-associated IFN-. When we examined fur-
ther the level of activation of lung draining LN T cells, we
found that those CD4 T cells that were IL-17RB had in-
creased expression of two critical transcription factors associ-
ated with cytokine production—GATA3 and T-bet (Fig. 1E).
Interestingly, previous studies have identified that IL-17RB was
expressed primarily on effector/memory T cells [18, 19]. In
contrast, not only were there fewer IL-17RB CD8 T cells, but
also, they did not express higher transcription factors (Fig.
1E). Thus, whereas IL-25 has been shown to up-regulate
GATA3 expression, its receptor may be expressed generally on
activated CD4 T cells and once expressed, enhance the pro-
duction of cytokines.
To investigate further the role of IL-25 in the inflammatory
response to RSV infection, mice infected with RSV were
treated with a polyclonal antibody to IL-25. The effects of anti-
IL-25 therapy in mice were assessed on Day 10 postinfection,
corresponding to peak pathophysiology in our model. RSV-
infected mice, treated with anti-IL-25 antibody, had a signifi-
cant reduction in AHR (Fig. 2A), as well as in the mucus-asso-
ciated gene gob5 (Fig. 2B). Histologic analysis confirmed that
inhibiting IL-25 reduced airway pathology and mucus (Fig.
2C); however, it did not affect specific subsets of inflammatory
cells in the lung (Fig. 2D). Next, the draining LNs of RSV-in-
fected animals were collected and restimulated in vitro to as-
Figure 2. Blockade of IL-25 during RSV infection in Balb/c mice attenuates goblet cell-associ-
ated pathology and mucus production. Naive Balb/c mice were infected with RSV (1105
PFU/mouse), treated with control or anti-IL-25 polyclonal rabbit anti-mouse antibody on Days
0, 2, 4, and 6, and harvested on Day 8. (A) AHR and (B) mucus-associated pulmonary gob5
expression after 8 days of infection. Cab, control antibody; Ctrl, control. (C) Histologic assessment of PAS-stained lung sections illustrates a reduc-
tion in mucus-stained airways (pink). (D) Flow cytometric assessment of individual immune cell populations in lungs of infected mice depicts no
reduction in cell accumulation. Mono, Monocyte; M, macrophage; cDC, conventional dendritic cell; Macs, macrophages. (E) RSV-restimulated
lung draining LN culture supernatants were assayed by Bioplex for cytokine levels. Data represent mean  se from five mice/group. *P  0.05
and is representative of three repeat studies.
Petersen et al. IL-25 in RSV disease
www.jleukbio.org Volume 95, May 2014 Journal of Leukocyte Biology 811
sess the effects of IL-25 blockade on antigen-specific cytokine
production (Fig. 2E). RSV-restimulated LN cells from mice
treated with control IgG produced type 2 cytokines in re-
sponse to RSV, whereas LN cells from animals that had been
treated with anti-IL-25 antibody showed dramatic reductions in
production of type 2 cytokines. In contrast, the expression of
IL-17a and IFN- was increased significantly in those animals
treated with anti-IL-25. Therefore, these results indicate that
IL-25 inhibition altered the activation of RSV-specific T lym-
phocytes and skewed the response to a less-pathogenic pheno-
type. Numerous studies have demonstrated that IL-25 regulates
Th1 and Th17 immune responses [20–22], and most recently,
the expression of IL-25 in the gut mucosa can regulate inflam-
matory bowel disease via IL-10 [23]. Interestingly, our studies
did not observe any effect on viral clearance with anti-IL-25
treatment (data not shown). The expression of IL-17RB may
provide a regulatory effect to inflammatory responses that can
help protect tissue at mucosal surfaces. However, in the case
of RSV, IL-25 overexpression may be linked to immunopatho-
genesis, especially in susceptible patient populations, including
those with underlying pulmonary diseases, such as asthma.
RSV infection of IL-17RB/ mice demonstrates
reduced pathogenic responses
To lend genetic proof to support our findings, IL-17RB/
mice, which lack the ability to respond to IL-25, were infected
with RSV. After 8 days of infection, IL-17RB/ mice showed
diminished pathology following RSV infection, including a re-
duction in airway inflammation and mucus hypersecretion
(Fig. 3A). The reduced pathologic severity was accompanied
by increased clearance of the virus, as depicted by expression
of RSV G protein mRNA expression in the lungs of IL-
17RB/ mice compared with WT mice (Fig. 3B). There was a
reduction in pulmonary cytokine transcripts, including IL-5,
IL-13, and IFN- (Fig. 3C). Furthermore, cytokine production
in draining LN cultures demonstrated the importance of IL-25
in regulating the antigen-specific response to RSV infection
(Fig. 3D). Similar to the anti-IL-25-treated animals, there was a
reduction in Th2 cytokines with a striking and significant in-
crease in IL-17 production. When we examined transcription
factor expression from the restimulated LNs of infected mice,
we observed a decrease in GATA3 and T-bet in IL-17RB/
mice (Fig. 3E). Examination of IL-17RB/ T cells demon-
strated that in the absence of IL-25 signaling, T cells are capa-
ble of responding to antigen and of producing cytokine (as
evidenced by IL-17A in response to RSV). Taken together,
these findings indicate that T cells may require activation be-
fore becoming IL-25-responsive and that activation itself can
occur in an IL-25-independent manner. However, as described
previously [24–26], IL-25 may act as an additional polarizing
signal for antigen-dependent responses, enabling T cells to
differentiate and mount a Th2 response in situations where
IL-25 is being produced, such as allergic asthma and RSV in-
fection. The alteration of immune responses and shift in the
phenotype and reduced lung pathology are consistent with the
findings with anti-IL-25 treatment and the reduction in the
cytokine, and transcription factor levels may be reflective of
more-efficient viral clearance. Interestingly, in studies from
Figure 3. Infection of IL-17RB/
C5BL/6 mice demonstrates a reduc-
tion in disease pathology and altera-
tion of cytokine responses. (A) Exam-
ination of lung pathology, 8 days
post-RSV infection, demonstrated a
reduction in inflammation and PAS-
stained mucus production. (B) Quan-
titative PCR of RSV G protein in the
lungs of 8-day-infected mice. The cy-
tokine mRNA expression in the lungs
(C) and protein in RSV-rechallenge
draining LN cells (D) displayed a dif-
ferent profile in IL-17RB/ mice.
(E) The mRNA expression of GATA3 and T-bet transcription factors was reduced in IL-17RB/ mice. Data represent mean  se from five mice/
group and are representative of three repeat studies. *P  0.05.
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our lab and others, IL-17 has been suggested to contribute to
lung pathology, in particular, to mucus hypersecretion. How-
ever, in the case of IL-25 neutralization or in IL-17RB/
mice, when Th2 cytokines are reduced, the increased IL-17
does not lead to more pathogenesis. We have observed this
aspect previously in studies with RSV vaccine development
[27], where high levels of IL-17 in the absence of Th2 cyto-
kines do not promote enhanced disease, suggesting that the
most-severe disease occurs when a combined set of mediators
is present.
Inhibition of IL-25 signaling impacts RSV-induced
allergic inflammation significantly
Childhood viral infections have multiple effects on the risk for
an eventual asthma diagnosis [28]. For example, individuals
with sensitivities to house dust mite are at an up to sevenfold-
higher risk for asthma if they experience a severe respiratory
infection—RSV or rhinovirus [29]—supporting the fact that
genetic predisposition plays an important role [30], as chil-
dren hospitalized with RSV bronchiolitis before their first
birthday are at a fivefold-increased risk of asthma if one parent
has a history of allergic disease [31]. Thus, an individual that
is susceptible to allergic disease or has underlying allergen sen-
sitivity may be more sensitive to adverse affects of RSV infec-
tion. To understand whether IL-25 influences the ability of
RSV to exacerbate allergic disease, we used a model of allergic
asthma to simulate a viral exacerbation with RSV. WT and IL-
17RB/ mice were sensitized to allergen, as described previ-
ously [14], infected with RSV during the active allergic re-
sponses, and then challenged with allergen during the course
of RSV infection (Day 5 postinfection). Our initial character-
ization of RSV-induced exacerbation demonstrated a signifi-
cant increase in IL-25 mRNA expression that corresponded to
a significant increase in IL-17RB CD11b, GR1 granulocytes
(Fig. 4A), which we have characterized previously as playing an
important role in driving airway pathology [32]. The data also
indicate that there was a significant increase in IL-17RB CD4
T cells during allergen-induced responses that were not in-
creased further by RSV exacerbation (Fig. 4A). No significant
increase in NKT cells was observed in our RSV infection
model and no change in number of IL-17RB NKT cells dur-
ing exacerbation (data not shown), in contrast to observations
in previous studies [10]. When we examined cellular changes
in the total cell subsets in allergic mice exacerbated with RSV,
we observed no significant change in any subset, although
some reduction in CD4CD69 (activated) T cells was ob-
served in the IL-17RB/ mice (Fig. 4B), which may have
been a result of increased viral clearance. As histology indi-
cates, increases in infiltrates were observed during the RSV-
induced exacerbation, and the absence of IL-17RB did not
Figure 4. RSV-induced exacerbation of allergic airway responses is
attenuated in IL-17RB/ C57BL/6 mice. Allergic mice were in-
fected with RSV and challenge two times with allergen (see Mate-
rials and Methods) to expose animals simultaneously to the stim-
uli. (A) Flow cytometry analyses indicated that the primary IL-
17RB cell population that was increased was granulocytes. (B)
Analysis of all leukocyte subsets indicated no significant change in
any individual population. (C) Histological examination reflected
the flow cytometry analysis in (B) indicating similar inflammatory
cell accumulation in IL-17RB/ mice; however, a reduced inten-
sity in the PAS-postitive staining was evident in the RSV-exacer-
bated animals compared with WT. Arrows indicate PAS-stained
goblet cells. (D) Quantitative PCR analysis of whole lung mRNA
indicated that RSV-exacerbated IL-17RB/ animals demonstrated a
reduction in IL-13 and gob5 mucus gene expression. Muc5AC, Mu-
cin 5AC. Data represent mean  se from five mice/group.*P  0.05;
**P0.01. This study was repeated twice with similar results.
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subjectively have an obvious decrease in cell infiltration
(Fig. 4C). Studies with RSV infection response alone identi-
fied that CD4 T cells were the primary pathogenic targets
for IL-25 activation, with few IL-17RB granulocytes. How-
ever, when examining a RSV-induced allergen exacerbation,
the most prominent IL-17RB cell population that in-
creased was a granulocytic cell. We have termed this previ-
ously subset type 2 myeloid cells that produced IL-4 and
IL-13 and were closely related to eosinophils [32]. Multiple
subsets of myeloid cells appear to express IL-17RB, includ-
ing basophils [33]. Interestingly eosinophil numbers, as-
sessed by flow and specific granule stain, were not changed
upon RSV exacerbation, matching our earlier observations
[14]. Thus, there appear to be multiple subsets of leuko-
cytes that express IL-17RB and have the ability to respond
to IL-25 and impact severity of disease. However, the most
apparent difference histologically between groups was the
reduction in mucus production in the RSV-exacerbated
IL-17RB/ group, with RSV-allergen-exacerbated WT mice
displaying more intense staining than the IL-17RB/ mice,
as indicated by the arrows (Fig. 4C). The analysis of lung
mRNA expression demonstrated substantial reduction in the
level of RSV-exacerbated IL-13 and the mucus associated
gene gob5 in the IL-17RB/ mice, confirming the histo-
logic picture in Fig. 4C (Fig. 4D). Thus, overall, there ap-
peared to be a significant reduction in the RSV-induced al-
lergic airway exacerbation response in the absence of
IL-17RB, characterized by an alteration of pathology. The
latter aspect may reflect enhanced clearance of RSV that
would ultimately lead to decreased immune activation.
Other recent studies have also highlighted that IL-17A can
provide pathogenic signals that promote an enhanced disease
phenotype associated with PMNs and mucus hypersecretion
[34–36]. As IL-17A and IL-25 (IL-17E) share a common recep-
tor chain—IL-17RA—and have common signaling properties,
including a steroid-resistant phenotype [32, 37], targeting the
common receptor may be beneficial. Recent strategies include
mAb to the IL-17RA chain that target the binding of IL-17A
and IL-25 [38]. This latter strategy may be important, given
the cross-regulatory effect that IL-25 and IL-17A appear to
have for one another. In the context of RSV infection, where a
dysregulated inflammatory response drives disease pathology,
the ability to regulate IL-17- and IL-25-induced inflammatory
signals could represent a powerful tool for preventing un-
wanted consequences of viral infection. Our data suggest that
significant pathologic components associated with RSV infec-
tion and asthma exacerbation may be managed effectively
through the targeting of IL-25-mediated activation.
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